12700 related articles for article (PubMed ID: 10711641)
21. Serum TNF-α, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-α2b treatment of patients with melanoma.
Hofmann MA; Kiecker F; Küchler I; Kors C; Trefzer U
J Cancer Res Clin Oncol; 2011 Mar; 137(3):455-62. PubMed ID: 20454974
[TBL] [Abstract][Full Text] [Related]
22. A sequential four-drug chemotherapy and biotherapy with interferon alpha and GM-CSF--an innovative protocol for the treatment of metastatic melanoma.
Schachter J; Rakowsky E; Sulkes A; Adler A
Cancer Biother Radiopharm; 1998 Jun; 13(3):155-64. PubMed ID: 10850351
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
[TBL] [Abstract][Full Text] [Related]
24. Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability.
Belli F; Arienti F; Sulé-Suso J; Clemente C; Mascheroni L; Cattelan A; Santantonio C; Gallino GF; Melani C; Rao S; Colombo MP; Maio M; Cascinelli N; Parmiani G
Cancer Immunol Immunother; 1997 Jun; 44(4):197-203. PubMed ID: 9222277
[TBL] [Abstract][Full Text] [Related]
25. Significance of pre-treatment immunological parameters in colorectal cancer patients with unresectable metastases to the liver.
Zaloudik J; Lauerova L; Janakova L; Talac R; Simickova M; Nekulova M; Mikulikova I; Kovarik J; Sheard M
Hepatogastroenterology; 1999; 46(25):220-7. PubMed ID: 10228796
[TBL] [Abstract][Full Text] [Related]
26. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2.
Lissoni P; Tisi E; Brivio F; Barni S; Rovelli F; Perego M; Tancini G
Eur J Cancer; 1991; 27(8):1014-6. PubMed ID: 1832885
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results.
Buzaid AC; Grimm EA; Ali-Osman F; Ring S; Eton O; Papadopoulos NE; Bedikian A; Plager C; Legha SS; Benjamin R
Melanoma Res; 1994 Oct; 4(5):327-30. PubMed ID: 7858418
[TBL] [Abstract][Full Text] [Related]
28. Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
Thompson JA; Gold PJ; Fefer A
Semin Oncol; 1997 Feb; 24(1 Suppl 4):S44-8. PubMed ID: 9122734
[TBL] [Abstract][Full Text] [Related]
29. Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study.
Tartour E; Blay JY; Dorval T; Escudier B; Mosseri V; Douillard JY; Deneux L; Gorin I; Negrier S; Mathiot C; Pouillart P; Fridman WH
J Clin Oncol; 1996 May; 14(5):1697-703. PubMed ID: 8622090
[TBL] [Abstract][Full Text] [Related]
30. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
[TBL] [Abstract][Full Text] [Related]
31. Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response.
Lauerova L; Dusek L; Simickova M; Kocák I; Vagundová M; Zaloudík J; Kovarík J
Neoplasma; 2002; 49(3):159-66. PubMed ID: 12098001
[TBL] [Abstract][Full Text] [Related]
32. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
33. Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy.
Maes M; Capuron L; Ravaud A; Gualde N; Bosmans E; Egyed B; Dantzer R; Neveu PJ
Neuropsychopharmacology; 2001 Feb; 24(2):130-40. PubMed ID: 11120395
[TBL] [Abstract][Full Text] [Related]
34. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
35. Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?
Lissoni P; Brivio F; Viviani S; Fumagalli L
J Biol Regul Homeost Agents; 1999; 13(2):110-4. PubMed ID: 10503734
[TBL] [Abstract][Full Text] [Related]
36. In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients.
Konjević G; Mirjačić Martinović K; Vuletić A; Babović N
Melanoma Res; 2010 Dec; 20(6):459-67. PubMed ID: 20938360
[TBL] [Abstract][Full Text] [Related]
37. Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma.
Vuoristo MS; Laine S; Huhtala H; Parvinen LM; Hahka-Kemppinen M; Korpela M; Kumpulainen E; Kellokumpu-Lehtinen P
Eur J Cancer; 2001 Sep; 37(13):1629-34. PubMed ID: 11527688
[TBL] [Abstract][Full Text] [Related]
38. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
Ridolfi L; Fiorentini G; Guida M; Michiara M; Freschi A; Aitini E; Ballardini M; Bichisao E; Ridolfi R;
Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
[TBL] [Abstract][Full Text] [Related]
39. The value of serum S-100beta and interleukins as tumour markers in advanced melanoma.
Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Parvinen LM; Hahka-Kemppinen M; Korpela M; Kumpulainen E
Melanoma Res; 2000 Jun; 10(3):237-41. PubMed ID: 10890377
[TBL] [Abstract][Full Text] [Related]
40. The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group program.
Keilholz U; Eggermont AM
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S99-103. PubMed ID: 10685668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]